Results 141 to 150 of about 3,648 (184)

Radiolabeled Angiopep‐2 Peptide Vector as a Preclinical Platform for Blood–Brain Barrier Targeting: Synthesis, Radiolabeling, and Preliminary In Vivo Biodistribution in Mice

open access: yesJournal of Peptide Science, Volume 32, Issue 7, July 2026.
The developed DOTA‐Angiopep‐2 conjugate was well tolerated in glioma cells and enabled high‐yield radiolabeling with 177Lu and 161Tb. The 161Tb conjugate showed brain delivery with predominantly renal clearance, supporting a stable radiotheranostic platform for BBB‐targeted glioma therapy and SPECT imaging.
Evgenia Fotou   +10 more
wiley   +1 more source

Pharmacological treatment with a GABA(A) receptor modulator and a selective serotonin reuptake inhibitor as a mitigation strategy against aircraft noise‐induced cardiovascular and neuronal damage

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 13, Page 3762-3779, July 2026.
Abstract Background and Purpose Noise pollution, particularly by aircraft, is a significant risk factor for cardiovascular disease. Aircraft noise activates stress response pathways in the brain, via the amygdala, the sympathetic nervous system and the hypothalamic–pituitary–adrenal axis.
Ivana Kuntić   +25 more
wiley   +1 more source

Comparative Analysis of Incidental and Non‐Incidental Papillary Thyroid Microcarcinoma Outcomes: Implications on Management Recommendations

open access: yesClinical Endocrinology, Volume 105, Issue 1, Page 100-107, July 2026.
ABSTRACT Introduction Papillary thyroid microcarcinomas (PTMC) are defined by the World Health Organisation (WHO) as tumours measuring ≤ 10 mm. Incidental PTMCs, or lesions discovered postoperatively on histological examination, are less extensively studied compared with lesions diagnosed preoperatively through cytology, particularly in terms of ...
Emma A. Finnegan   +6 more
wiley   +1 more source

Life on Mars? The physiological perspective

open access: yes
Experimental Physiology, EarlyView.
Ronan M. G. Berg, Damian M. Bailey
wiley   +1 more source

The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long‐Acting Insulin Analogues for Diabetes Mellitus

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5527-5541, July 2026.
ABSTRACT In the year 2000 the first once daily long‐acting bioengineered insulin analogue (LAIA), insulin glargine (‘glargine’), a true basal insulin (BI), became available for clinical use. This led to the decline in the 50‐year‐old era and prominence of the intermediate‐acting insulins, neutral protamine Hagedorn (NPH) and lente, requiring twice ...
Geremia B. Bolli   +9 more
wiley   +1 more source

Development of a business continuity plan and implementation of headquarters operation training considering a nuclear disaster. [PDF]

open access: yesFront Public Health
Tsujiguchi T   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy